CODIGO : 172290

NOMBRE PACIENTE : ITHAN ALEXANDER FORERO BARRERA **SEXO :** MASCULINO

FECHA DE NACIMIENTO : 10/11/2025 **REGISTRO CIVIL :** 1,070,404,869

NOMBRE RESPONSABLE : MARIA ALEJANDRA BARRERA GALVIS

DOC.IDENTIDAD DE LA MADRE : 1,192,762,953

FECHA TOMA DE MUESTRA : 10/02/2026 **TIPO DE MUESTRA :** TALÓN

FECHA DE IMPRESIÓN : 27/02/2026 **PESO :** 2730

TAMIZAJE NEONATAL

ANÁLISIS MUESTRA DE SANGRE

	RESULTADO	VALORES DE REFERENCIA	INTERPRETACIÓN
T.S.H Neonatal	2.48	>= 6 µl/mL talón en prematuros >= 10 µl/mL talón >= 15 µl/mL cordón	Normal
Deficiencia de G6PDH	5.30	> 2.6 U/gHb	Normal

TÉCNICA: Fluoroinmunoensayo (Delfia). *Procesado en Colombia por PREGEN.*

Hemoglobinopatías	AF	Ausencia de hemoglobinas anormales	Normal

TÉCNICA: Cromatografía Liquida de Alto Rendimiento (HPLC). *Procesado en Colombia por PREGEN.*

TAMIZAJE AMPLIADO

ESPECTROMETRIA DE MASAS EN TANDEM

Procesado en Archimedlife international medical laboratory. 1110 Vienna.

DESORDENES DE AMINOÁCIDOS

Citrulina, Metionina, Leucina, Isoleucina, Valina, Fenilalanina, Tirosina.

Ausencia de metabolitos anormales — Normal

PERFIL DE ACILCARNITINAS

C16,C18,C18:1,C16OH,C18:1OH,C8,C10:1,C5,C5DC,C4,C14,C14:1,C50H,C3,C5:1

Ausencia de metabolitos anormales — Normal

RESULTADOS NORMALES

Recuerde que estas son pruebas de tamizaje que solo indican la probabilidad de que el recién nacido tenga una de las enfermedades estudiadas por el programa y pueden requerir pruebas adicionales para la confirmación de algún diagnóstico. La sensibilidad de estas pruebas se reduce a medida que aumenta la edad del paciente, por esto es conveniente realizarlas dentro del primer mes de nacido.

REVISADO : EDUVILIA JOHANA GOMEZ
Bacterióloga
Reg. 40.936.003

PROCESADO : MARIA JOSE PINZON GARCIA
Bacterióloga
Reg. 1.015.469.392

FECHA : 27/02/2026

- - - - - - - - - - - - - - - - - - - -

`LABORATORIO PREGEN
Carrera 15a No 106-42
BOGOTA

Batch 2074, Rack A, Plate 1, Well E11, 172290 AF
[C923210EC9A40CC8] Feb 13, 2026 17:00:57 Pressure = 52 bar (50 to 53)



PEAK	RT	REL RT	% CONC	AREA	COMMENT
1	0.397	F 0.19	4.0%	59838	
2	0.542	F 0.26	3.4%	51013	
3	0.828	F 0.41	0.6%	8293	
4	0.947	F 0.46	7.4%	111761	
5	1.748	F 0.85	1.6%	24109	
6	2.035	F 1.00	14.9%	223334	Consistent with F
7	2.560	F 1.25	0.5%	6812	
8	2.730	F 1.33	2.3%	35218	
9	3.030	A 0.79	2.0%	29558	
10	3.285	A 0.85	0.4%	5732	
11	3.825	A 1.00	61.1%	916576	A peak - REVIEW
12	4.310	A 1.12	0.2%	3445	
13	4.593	A 1.20	1.6%	24600	Consistent with E
			Total Area:	1500289	

Codes: 1) Wide A peak
2) Area of A peak < 80%
3) Peak area greater than expected
4) Peak after A2
5) A1c > 10%
6) HbF or variant present
7) Total sample area too small/big
8) A2 is not within normal range

baby health check©

+ARCHIMEDlife Laboratory has been designated as a medical laboratory with the identification number 0407 from Accreditation Austria/Federal Ministry for Digitization and Business Location for the areas listed and published at: www.bmaw.gv.at/akkreditierung.

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGEN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report	27.02.2026
Sample Received	19.02.2026
Date of Sampling	09.02.2026
LAB-ID	262006989

Medical Report

Patient name	**FORERO BARRERA ITHAN ALEXANDER**	Sample-ID	A0361342
Date of Birth	**14.11.2025**	Gender	M

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot. qPCR from Dried Blood Spot.

Results:

Parameter	Value	Unit	Reference
Birth weight (g)	2730	g	-
17-hydroxyprogesterone (17OHP)	<5.0	nmol/L	< 90.0
Thyroid-stimulating hormone (TSH)	1.0	µU/mL	< 15.0
Biotinidase	437.9	U	> 51.0
Galactose-1-P-uridyltransferase (GALT)	10.1	U/g Hb	> 2.5
Immunoreactive trypsinogen (IRT)	18.1	ng/mL	< 65.0
Phenylalanine	22.5	µmol/L	< 150.0
Amino acid profile	negative		-
Acylcarnitine profile	negative		-

Interpretation: NEGATIVE RESULT

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife®
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria | www.archimedlife.com

Patient name	**FORERO BARRERA ITHAN ALEXANDER**
Date of Birth	**14.11.2025**

Sample-ID	A0361342
Gender	M

Results:

Parameter	Value	Unit	Reference
Phenylalanine (Phe)	22.5	µmol/L	< 150.0
Phenylalanine / Tyrosine ratio (Phe/Tyr)	0.46	µmol/L	< 2.20
Tyrosine (Tyr)	48.8	µmol/L	< 200.0
Leucine (Leu)	80.6	µmol/L	< 270.0
Valine (Val)	45.4	µmol/L	< 200.0
Methionine (MET)	18.7	µmol/L	< 78.0
Methionine / Phenylalanine (Met/Phe)	0.83	µmol/L	< 1.60
Citrulline (Cit)	11.9	µmol/L	< 50.0
Ornithine (Orn)	105.3	µmol/L	< 250.0
Ornithine / Citrulline ratio (Orn/Cit)	8.85	µmol/L	1.50 - 20.00
Proline (Pro)	88.3	µmol/L	< 350.0
Alanine (Ala)	137.2	µmol/L	< 750.0
Arginine (Arg)	23.8	µmol/L	< 100.0
Aspartic acid (Asp)	67.9	µmol/L	< 100.0
Glutamic acid (Glu)	202.4	µmol/L	< 600.0
Glycamine (Gly)	126.6	µmol/L	< 700.0
Free carnitine (C0)	21.33	µmol/L	6.00 - 100.00
acetylcarnitine (C2)	16.82	µmol/L	1.34 - 48.81
propionylcarnitine (C3)	2.78	µmol/L	0.13 - 6.60
butyryl-/isobutyrylcarnitine (C4)	0.17	µmol/L	0.03 - 0.90
isovaleryl-/2-methylbutyrylcarnitine(C5)	0.10	µmol/L	0.02 - 2.00
tiglylcarnitine (C5:1)	0.01	µmol/L	< 0.20
hydroxyvalerylcarnitine (C5OH)	0.13	µmol/L	0.02 - 0.57
glutarylcarnitine (C5DC)	0.03	µmol/L	< 0.30
hexanoylcarnitine (C6)	0.07	µmol/L	0.01 - 0.13
octanoylcarnitine (C8)	0.04	µmol/L	0.01 - 0.30
decanoylcarnitine (C10)	0.04	µmol/L	0.01 - 0.36
decenoylcarnitine (C10:1)	0.16	µmol/L	< 0.30
decadienoylcarnitine (C10:2)	0.04	µmol/L	< 0.10
dodecanoylcarnitine (C12)	0.05	µmol/L	0.10 - 0.60
myristoylcarnitine (C14)	0.16	µmol/L	0.01 - 0.57
tetradecenoylcarnitine (C14:1)	0.07	µmol/L	0.10 - 0.38
palmitoylcarnitine (C16)	1.08	µmol/L	0.62 - 7.81
3-hydroxypalmitoylcarnitine (C16OH)	0.02	µmol/L	< 0.10
stearoylcarnitine (C18)	0.62	µmol/L	0.30 - 2.40
oleylcarnitine (C18:1)	4.00	µmol/L	0.06 - 3.86
3-hydroxystearoylcarnitine (C18OH)	0.01	µmol/L	< 0.09
malonylcarnitine (C3DC)	0.03	µmol/L	< 0.50

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife GmbH
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria
www.archimedlife.com